Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
University of Amsterdam
Ámsterdam, HolandaPublicaciones en colaboración con investigadores/as de University of Amsterdam (7)
2023
-
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
JHEP Reports, Vol. 5, Núm. 5
-
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6
-
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression
European Radiology, Vol. 33, Núm. 1, pp. 493-500
2022
-
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
Cancer Imaging, Vol. 22, Núm. 1
-
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial
Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 9, pp. 2487-2496
2021
-
Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 75, Núm. 6, pp. 1387-1396
2019
-
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 71, Núm. 6, pp. 1164-1174